Low Protein A20 in Minor Salivary Glands is Associated with Lymphoma in Primary Sjögren's Syndrome

Scandinavian Journal of Immunology

Volumn 83, Issue 3, 2016, Pages 181-187

  Johnsen, S J A ^a   Gudlaugsson, E ^a   Skaland, I ^a   Janssen, E A M ^a   Jonsson, M V ^b   Helgeland, L ^c   Berget, E ^b   Jonsson, R ^b,c   Omdal, R ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN A20; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MALE; MARGINAL ZONE LYMPHOMA; MINOR SALIVA GLAND; PRIMARY SJOGREN SYNDROME; PRIORITY JOURNAL; SJOEGREN SYNDROME; VERY ELDERLY; IMMUNOLOGY; LYMPHOMA, B-CELL, MARGINAL ZONE; METABOLISM; MIDDLE AGED; PATHOLOGY; SALIVARY GLAND; SJOGREN'S SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; DNA-BINDING PROTEINS; FEMALE; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NF-KAPPA B; NUCLEAR PROTEINS; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 84960082055     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12405     Document Type: Article

References (35)

1. Jonsson R, Theander E, Sjostrom B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjögren's syndrome. JAMA 2013;310:1854-5.
2. Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S. The complexity of Sjögren's syndrome: Novel aspects on pathogenesis. Immunol Lett 2011;141:1-9.
3. Yao Y, Liu Z, Jallal B, Shen N, Ronnblom L. Type I interferons in Sjögren's syndrome. Autoimmun Rev 2013;12:558-66.
4. Youinou P, Saraux A, Pers JO. B-lymphocytes govern the pathogenesis of Sjögren's syndrome. Curr Pharm Biotechnol 2012;13:2071-7.
5. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803.
6. Johnsen SJ, Brun JG, Goransson LG et al. The risk of non-hodgkin's lymphoma in primary Sjögren's syndrome, a population-based study. Arthritis Care Res (Hoboken) 2012;65:816-21.
7. Theander E, Vasaitis L, Baecklund E et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011;70:1363-8.
8. Johnsen SJ, Berget E, Jonsson MV, Helgeland L, Omdal R, Jonsson R. Evaluation of Germinal Center-like Structures and B Cell Clonality in Patients with Primary Sjögren's Syndrome with and without Lymphoma. J Rheumatol 2014;41:2214-22.
9. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-6.
10. Nordmark G, Wang C, Vasaitis L et al. Association of genes in the NF-kappaB pathway with antibody positive primary Sjögren's syndrome. Scand J Immunol 2013;78:447-54.
11. Bende RJ, van Maldegem F, van Noesel CJ. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica 2009;94:1109-23.
12. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009;30:383-91.
13. Zhang M, Peng LL, Wang Y et al. Roles of A20 in autoimmune diseases. Immunol Res 2015; Jul 2 [Epub ahead of print].
14. Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol 2010;28:708-14.
15. Wang X, Zhu L, Liao Z et al. Alternative expression pattern of MALT1-A20-NF-kappaB in patients with rheumatoid arthritis. J Immunol Res 2014;2014:492872.
16. Vande Walle L, Van Opdenbosch N, Jacques P et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 2014;512:69-73.
17. Hah YS, Lee YR, Jun JS et al. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum 2010;62:2313-21.
18. Hymowitz SG, Wertz IE. A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer 2010;10:332-41.
19. Compagno M, Lim WK, Grunn A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-21.
20. Honma K, Tsuzuki S, Nakagawa M et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009;114:2467-75.
21. Novak U, Rinaldi A, Kwee I et al. The NF-kB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009;113:4918-21.
22. Kato M, Sanada M, Kato I et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-6.
23. Nocturne G, Boudaoud S, Miceli-Richard C et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjögren's syndrome. Blood 2013;122:4068-76.
24. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
25. Jaffe ESHN, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon: IARC Press; 2001
26. Musone SL, Taylor KE, Nititham J et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011;12:176-82.
27. Lessard CJ, Li H, Adrianto I et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet 2013;45:1284-92.
28. Lee EG, Boone DL, Chai S et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000;289:2350-4.
29. Chu Y, Vahl JC, Kumar D et al. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 2011;117:2227-36.
30. Tavares RM, Turer EE, Liu CL et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010;33:181-91.
31. Sisto M, Lisi S, Lofrumento DD, Ingravallo G, Maiorano E, D'Amore M. A failure of TNFAIP3 negative regulation maintains sustained NF-kappaB activation in Sjogren's syndrome. Histochem Cell Biol 2011;135:615-25.
32. Le Pottier L, Devauchelle V, Fautrel A et al. Ectopic germinal centers are rare in Sjögren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009;182:3540-7.
33. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders-what are the driving forces? Semin Cancer Biol 2014;24:61-70.
34. Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjögren's syndrome. Arthritis Rheum 2010;62:2605-10.
35. Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 2012;12:774-85.